#### MEMBERS PRESENT

Gary Franklin, MD, MPH (Co-chair), Washington	Shelly Gray, PharmD, School of Pharmacy,
State Department of Labor and	University of Washington
Industries	Jason Fodeman, MD, Washington State
Elizabeth Eckstrom, MD, Oregon Health	Department of Labor and Industries
Sciences University	Debra Gordon, RN, DNP, FAAN, University
Blake Maresh, MPA, CMBE, Washington State	of Washington School of Medicine
Department of Health	Jaymie Mai, PharmD, Washington State
Darcy Jaffe, Washington State Hospital	Department of Labor and Industries
Association	Angie Sparks, MD, Kaiser Permanente
Mark Sullivan, MD, PhD, University of	Washington
Washington	Steven Stanos, DO, Swedish Medical Center
Carla Ainsworth, MD, MPH, Iora Primary Care –	Michael Parchman, Kaiser Permanente
Central District	Research Institute
Pam Davies, MS, ARNP, FAANP, University of	Kushang Patel, MD, Anesthesiology and Pain
Washington	Medicine, University of Washington
Rose Bigham, Patient Advocate	Kara Shirley, PharmD, Oregon Health Authority
Siobhan Brown, MPH, CPH, CHES, Community	Gina Wolf, DC, American Chiropractic
Health Plan of Washington	Association

### STAFF AND MEMBERS OF THE PUBLIC

Nick Locke, MPH, Bree Collaborative	Terri Lewis
Monica Salgaonkar, MHA, Washington State	Diana Vinh
Medical Association	Yuliya Shirokova, University of Washington

### WELCOME

Gary Franklin, MD, MPH (Co-chair), Medical Director, Washington State Department of Labor and Industries welcomed members to the workgroup and ran through roll and introductions.

Action: To adopt the minutes **Result:** Unanimously approved

Dr. Franklin asked members about discontinuing the topic of different opioid treatments (like nonacting, short acting, and intermittent treatment). Members discussed:

- Interest in pursuing guidelines for using opioids to treat intermittent pain.
- Lack of literature in this field makes clear guidelines difficult
- In chat: "come clean on intermittent opioids and say that there is no literature on this or evidence, but common-sense advice is that as patients age you should reconsider the dose prescribed for intermittent use because of the risks of falls, etc."
- To table this topic for now, but review the available literature and guidelines to include language about prescribing for "flare-up" pain or intermittent pain.

### Non-pharmacologic Treatment of Pain in Older Adults

Kushang Patel, MD, Anesthesiology and Pain Medicine at the University of Washington discussed extra non-pharmacologic treatment of pain topics including aerobic exercise and strength training. Members discussed:

- The benefits and limitations of a large systematic review on the effects of noninvasive and nonpharmacological treatment for chronic pain.
  - Benefits: the study had a strict and well-defined inclusion criterion for a number of conditions ranging from low back pain to knee osteoarthritis.
  - Drawbacks: the frequency and scope of harms were not well defined, the inclusion criteria had rigid standards for follow-up, and some categories lacked trials on participants with a mean age above 60.
- Limitations of exercise to manage chronic pain
  - Exercise can lead to harms, fatigue, especially with older adult populations
  - Access and coverage issues related to exercise and strength training can become an equity issue for older adults managing pain.
- Key Takeaways
  - Most studies demonstrated that strength and aerobic training led to improvements in pain and function. The strength of association ranged from low to moderate.
  - Older adults require multiple modalities to manage chronic pain, such as prescription drugs, strength training, and mindfulness. RCTs do not readily capture the nuance of treatment plans.
  - When considering exercise as treatment, also important to think about motivation

While discussing multimodal care, including non-pharmacologic treatment options, several workgroup members raised concerns about accessibility of alternative treatment mechanisms, especially from an affordability and insurance coverage perspective. Several members expressed interest in continuing this conversation through comments and via the chat box.

# **Co-Prescribing with Opioids for Older Adults**

The co-prescribing with opioids subgroup presenting their recommendations, organized into categories for providers and health care systems. Members discussed:

- The evidence for co-prescribing guidelines come from literature that is not specific to opioids but draws from similar literature about medication review.
- The main goal is to prevent co-prescribing with opioids and CNS medication
- Language about gabapentinoids should be separate from language about CNS-active medications, specifically benzodiazepines
- Adding a box with tips about side effects to look out for if patients are taking both opioids and CNS-active medications
- Include information about reaching out to support from behavioral health teams when deprescribing CNS-active medications like benzodiazepines

# PUBLIC COMMENT AND GOOD OF THE ORDER

Dr. Franklin opened up space for public comment at the end of the meeting. Those present discussed:

• Pharmacogenetic assessment for potential interaction effects between prescription drugs, overthe-counter drugs, and any opioid prescriptions.

Dr. Franklin thanked all for attending and adjourned the meeting. Next month will focus on heat therapy and ACT.